US 12,268,683 B2
Compounds and methods for synergistic activation of M channels
Geoffrey W. Abbott, Irvine, CA (US); and Rian W. Manville, Irvine, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Appl. No. 17/260,796
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
PCT Filed Jul. 18, 2019, PCT No. PCT/US2019/042476
§ 371(c)(1), (2) Date Jan. 15, 2021,
PCT Pub. No. WO2020/018839, PCT Pub. Date Jan. 23, 2020.
Claims priority of provisional application 62/700,046, filed on Jul. 18, 2018.
Prior Publication US 2021/0267965 A1, Sep. 2, 2021
Int. Cl. A61K 31/4748 (2006.01); A61K 31/19 (2006.01); A61K 31/195 (2006.01); A61K 31/197 (2006.01); A61K 31/198 (2006.01); A61K 31/27 (2006.01); A61K 31/353 (2006.01); A61K 31/555 (2006.01)
CPC A61K 31/4748 (2013.01) [A61K 31/19 (2013.01); A61K 31/195 (2013.01); A61K 31/197 (2013.01); A61K 31/198 (2013.01); A61K 31/27 (2013.01); A61K 31/353 (2013.01); A61K 31/555 (2013.01)] 9 Claims
 
1. A composition comprising: 1-30 μM mallotoxin (MTX), 1-500 μM isovaleric acid (IVA), and about 1 μM retigabine (RTG).